96 related articles for article (PubMed ID: 23946872)
1. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.
Kozinn SI; Harty NJ; Delong JM; Deliyiannis C; Logvinenko T; Summerhayes IC; Libertino JA; Holway AH; Rieger-Christ KM
Genes Cancer; 2013 Jan; 4(1-2):61-9. PubMed ID: 23946872
[TBL] [Abstract][Full Text] [Related]
2. miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR.
Fuller RN; Vallejos PA; Kabagwira J; Liu T; Wang C; Wall NR
Front Genet; 2024; 15():1393353. PubMed ID: 38919953
[No Abstract] [Full Text] [Related]
3. Role of microRNAs and their downstream target transcription factors in zebrafish thrombopoiesis.
Al Qaryoute A; Fallatah W; Dhinoja S; Raman R; Jagadeeswaran P
Sci Rep; 2023 Sep; 13(1):16066. PubMed ID: 37752184
[TBL] [Abstract][Full Text] [Related]
4. Role of MicroRNAs and their Downstream Target Transcription Factors in Zebrafish Thrombopoiesis.
Qaryoute AA; Fallatah W; Dhinoja S; Raman R; Jagadeeswaran P
Res Sq; 2023 Apr; ():. PubMed ID: 37162944
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Regulatory Roles of miR-21, miR-15, and miR-let-7 in ABC Transporter-Mediated Chemoresistance: Implications for Breast Cancer Etiology and Treatment.
Khalaf BH; Suleiman AA; Suwaid MA
Mol Biotechnol; 2023 Dec; ():. PubMed ID: 38133750
[TBL] [Abstract][Full Text] [Related]
6. Dual mechanism of Let-7i in tumor progression.
Zhou J; Xiang H; Cao Z
Front Oncol; 2023; 13():1253191. PubMed ID: 37829341
[TBL] [Abstract][Full Text] [Related]
7. Implications of Decreased Expression of miR-125a with Respect to Its Variant Allele in the Pathogenesis of Recurrent Pregnancy Loss: A Study in a High Incidence Zone.
Manzoor U; Pandith AA; Amin I; Wani S; Sanadhya D; Lone TA; Mir H; Paray BA; Gulnaz A; Anwar I; Ahmad A; Aein QU
J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807118
[TBL] [Abstract][Full Text] [Related]
8. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.
Buchholz M; Strotmann J; Majchrzak-Stiller B; Hahn S; Peters I; Horn J; Müller T; Höhn P; Uhl W; Braumann C
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681665
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Yang J; Xu J; Zhang B; Tan Z; Meng Q; Hua J; Liu J; Wang W; Shi S; Yu X; Liang C
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681603
[TBL] [Abstract][Full Text] [Related]
10. Circular RNA_0000629 Suppresses Bladder Cancer Progression Mediating MicroRNA-1290/CDC73.
Wang J; Luo J; Wu X; Gao Z
Cancer Manag Res; 2021; 13():2701-2715. PubMed ID: 33790645
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells.
Namima D; Fujihara S; Iwama H; Fujita K; Matsui T; Nakahara M; Okamura M; Hirata M; Kono T; Fujita N; Yamana H; Kato K; Kamada H; Morishita A; Kobara H; Tsutsui K; Masaki T
In Vivo; 2020; 34(6):3195-3203. PubMed ID: 33144424
[TBL] [Abstract][Full Text] [Related]
12. miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer.
Cai Z; Zhang F; Chen W; Zhang J; Li H
Onco Targets Ther; 2019; 12():11805-11816. PubMed ID: 32099386
[TBL] [Abstract][Full Text] [Related]
13. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.
Braicu C; Buiga R; Cojocneanu R; Buse M; Raduly L; Pop LA; Chira S; Budisan L; Jurj A; Ciocan C; Magdo L; Irimie A; Dobrota F; Petrut B; Berindan-Neagoe I
J Exp Clin Cancer Res; 2019 Oct; 38(1):433. PubMed ID: 31665050
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs: Key Players in Bladder Cancer.
Li Q; Wang H; Peng H; Huang Q; Huyan T; Huang Q; Yang H; Shi J
Mol Diagn Ther; 2019 Oct; 23(5):579-601. PubMed ID: 31325035
[TBL] [Abstract][Full Text] [Related]
15. let-7i inhibits proliferation and migration of bladder cancer cells by targeting HMGA1.
Qin MM; Chai X; Huang HB; Feng G; Li XN; Zhang J; Zheng R; Liu XC; Pu C
BMC Urol; 2019 Jun; 19(1):53. PubMed ID: 31196036
[TBL] [Abstract][Full Text] [Related]
16. The Network of Non-coding RNAs in Cancer Drug Resistance.
Corrà F; Agnoletto C; Minotti L; Baldassari F; Volinia S
Front Oncol; 2018; 8():327. PubMed ID: 30211115
[TBL] [Abstract][Full Text] [Related]
17. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Chen Z; Zheng Y; Shi Y; Cui Z
Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
[TBL] [Abstract][Full Text] [Related]
18. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.
Ayers D; Vandesompele J
Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273813
[TBL] [Abstract][Full Text] [Related]
19. Advances in miRNA-Mediated Mucin Regulation.
Krishn SR; Batra SK; Kaur S
Curr Pharmacol Rep; 2015 Dec; 1(6):355-364. PubMed ID: 27867838
[TBL] [Abstract][Full Text] [Related]
20. Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.
Zang Z; Guan W; Chen D; Han Y; Shi Z; Zhou J
Med Sci Monit; 2016 Nov; 22():4186-4192. PubMed ID: 27814341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
